Pharmacoeconomic analysis of adjuvant use of zonisamide therapy resistant partial epilepsy in adults
The purpose of pharmacoeconomic studies of the drug zonisamide is to determine it’s clinical and cost-effectiveness in adult patients with refractory partial epilepsy in comparison with other new antiepileptic drugs in the conditions of the Russian Federation. Target population are Russian patients...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2018-06-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/203 |
| Summary: | The purpose of pharmacoeconomic studies of the drug zonisamide is to determine it’s clinical and cost-effectiveness in adult patients with refractory partial epilepsy in comparison with other new antiepileptic drugs in the conditions of the Russian Federation. Target population are Russian patients older than 18 years with the diagnosis of the resistant partial epilepsy with secondary generalization or without it. Results of pharmacoeconomic modeling analysis application zonisamide and topiramate therapy in partial epilepsy for 2 years under the Russian healthcare system on one patient showed that all the above drugs were effective in the treatment of refractory partial epilepsy in their nomination in addition to other antiepileptic drugs. Comparing the efficacy, expressed in the probability of therapeutic response ≥50% after 2 years of treatment, topiramate at — 0.227, zonisamide — 0.194. The cost of the use of drugs is higher in comparison topiramate — 115 082 rubles, zonisamide — 97 342 rubles. Cost-effectiveness ratio (CER) was the lowest in zonisamide — 501 070 rubles, topiramate — 507 762 rubles. QALY at zonisamide — 1,189, topiramate — 1,191. Cost-utility ratio (CUR) was the lowest in zonisamide — 81 886 rubles, topiramate — 96 609 rubles. For all drugs increased doses resulted in an increase of efficiency of treatment, as well as the frequency of adverse events and associated with them, cessation of therapy. With increasing doses up to the maximum performance CER and CUR will be at least topiramate. None of the compared drugs does not exceed the threshold of «willingness to pay ratio», i.e. they are all pharmacoeconomical and be reimbursement. Th e budget impact analysis showed that the overall cost of the therapy will be higher in the group of topiramate is 15.4%, compared with zonisamide. Pharmacoeconomic analysis confirmed the data on effi cacy and safety, and also showed the place of comparators in the cost of treatment of patients with partial epilepsy. |
|---|---|
| ISSN: | 2588-0519 2618-8473 |